From: A 1-year analysis of adverse events following COVID-19 vaccination in Lebanon: a retrospective study
 | Total | PZ | AZ | p value |
---|---|---|---|---|
Case report, N (%) | 68 (100) | 55 (80.88) | 13 (19.12) | Â |
Age, Mean ± SD | 63.62 ± 20.23 | 66.9 ± 20.6 | 49.8 ± 11.3 | 0.002* |
Gender, N (%) | ||||
 Male | 36 (52.9) | 30 (54.55) | 6 (76.15) | 0.586 |
 Female | 32 (47.1) | 25 (45.45) | 7 (53.85) | |
Onset of AEFIs, N (%) | ||||
 After dose 1 | 40 (58.8) | 30 (54.55) | 10 (76.93) | 0.089 |
 After dose 2 | 24 (35.3) | 22 (40) | 2 (15.38) | |
 After dose 3 | 3 (4.4) | 3 (5.45) | 0 | |
 After dose 1 and 2a | 1 (1.5) | 0 | 1 (7.69) | |
TTO per dose administered, Mean ± SD | ||||
 After dose1 | 8.55 ± 7.96 | 7.6 ± 7.31 | 11.4 ± 9.5 | 0.706 |
 After dose 2 | 10.63 ± 19.63 | 11.33 ± 20.91 | 3.5 ± 2.12 | |
 After dose 3 | 7.33 | 7.33 ± 11.85 | – | |
 After dose 1 and 2a | 9 | – | 9 | |
Seriousness criteria, N (%) | ||||
 Fatal | 19 (27.9) | 15 (27.27) | 4 (30.77) | 0.801 |
 Hospitalized | 49 (72.1) | 40 (72.73) | 9 (69.23) | |
AEFI Committee decision, N (%) | ||||
 Coincidental | 36 (52.9) | 31 (56.36) | 5 (38.46) | 0.25 |
 Indeterminate | 24 (35.3) | 19 (34.55) | 5 (38.46) | |
 Consistent | 8 (11.8) | 5 (9.09) | 3 (23.08) |